A Case Report of Hyponatremia Associated with Maprotiline Treatment

Žana B. Stanković1, Zorana Z. Pavlović1,3, Milica J. Jovičić1, Miloš P. Žarković2,3

1 Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
2 Institute for Endocrinology, Diabetes and Diseases of metabolism, Clinical Centre of Serbia, Belgrade, Serbia
3 School of Medicine, University in Belgrade, Belgrade, Serbia

SUMMARY

**Background:** Maprotiline is a tricyclic antidepressant (sometimes classified as a tetracyclic antidepressant), which is predominantly a norepinephrine/noradrenaline reuptake inhibitor, commonly prescribed for depression.

**Aim:** To present a female patient with depressive episode and occurrence of hyponatremia during the maprotiline treatment.

**Case Report:** A 62-year-old female was diagnosed with depressive episode four years ago. She was treated ambulatory with maprotiline 50mg/day and bromazepam 6mg/day, from local psychiatrist. The patients also used enalapril 2x10 mg/day, metoprolol 2x50 mg/day, nifedipine 5 mg/day and simvastatin 20 mg/day for treating hypertension and dyslipidemia. After about 12 months of maprotiline use she was hospitalized at the Endocrinology unit of a local hospital due to appearance of confusion, unstable walking, cramps, as well as an increase in blood pressure. Then diagnosed hyponatremia (serum sodium level-112 mmol/L), corrected (137 mmol/L) by using parenteral therapy. The patient continued to use maprotiline without consultation with her psychiatrist. After one year, the patient was hospitalized at the Endocrinology unit of tertiary level due to detailed re-examination because of recurrent hyponatremia (117 mmol/L), corrected (136 mmol/L) by ambulatory use of parenteral therapy at a local hospital. Water test load was used and the Syndrome of inappropriate antidiuretic hormone secretion was diagnosed. Insulin Tolerance Test showed preserved the integrity of the hypothalamic-pituitary-adrenal axis. Antidepressant mirtazapine (15 mg/day) was introduced due to recurrence of depression. Gradual reduction of depressive symptoms was observed to mirtazapine. Antihypertensive therapy, restriction of fluid intake and dietary regimen were still applied. Serum sodium concentrations were in the normal ranges over the past 18 months.

**Conclusion:** Serum sodium level should be measured before and during the therapy with any class of antidepressants, especially in those patients with increased risk of the hyponatremia occurrence.

**Keywords:** antidepressants, side effects, hyponatremia, maprotiline, mirtazapine
INTRODUCTION

Hyponatremia is an electrolyte abnormality which is clinically defined as serum sodium concentration of <135 mEq/L. This electrolyte disorder may be complication in the following diseases: heart failure, cirrhosis, adrenocortical insufficiency, diabetes mellitus or hyperglycemia, persistent diarrhea and/or vomiting, renal disorders, hypothyroidism, lower body weight, chronic obstructive pulmonary disease (COPD) and acquired immune deficiency syndrome (AIDS) [1].

Hyponatremia may occur as a side effect of a large number of different drugs, including nearly all psychotropics. Psychotropic drugs may cause hyponatremia by increasing hypothalamic production of antidiuretic hormone (ADH) [ antidepressants (ADs) (Tricyclic ADs, Selective serotonin reuptake inhibitors (SSRIs), Monoamine oxidase inhibitors (MAOIs), antipsychotics (phenothiazines, butyrophenones), antiepileptic drugs (oxcarbazepine, sodium valproate)], potentiating of ADH effect (antiepileptic drug lamotrigine), resetting osmostat [ADs (Serotonergic and Noradrenergic Reuptake Inhibitors (SNRIs) (venlafaxine, duloxetine), Dopamine Reuptake Inhibitors (DRIs) (bupropion)] or through all of the above mentioned mechanisms (antiepileptic drug carbamazepine), although the exact mechanisms remain unclear.

ADs are most strongly associated with hyponatremia from all psychotropics. According to the reference literature, the risk of hyponatremia is considerably greater with SSRIs and SNRIs in relation to other classes of ADs [1, 2, 3].

Non-psychotropic drugs that can induce hyponatremia are thiazides diuretics, angiotensin-converting enzyme (ACE) inhibitors, antineoplastic agents, proton pump inhibitors (PPIs), non-steroidal antiinflammatory drugs (NSAIDs), antidiabetic drugs, sulphpyrazone, analgesics, and exogenous forms of ADH (vasopressin, desmopressin) [4].

Hyponatremia caused by the use of ADs usually occurs within 2 weeks of starting therapy [4], but sometimes it may take many months [5]. Risk factors for hyponatremia associated with administration of antidepressants include older age, female gender, somatic comorbid conditions and concomitant therapy. Early symptoms of hyponatremia are nausea, vomiting, anorexia, disorientation, headache, fatigue, weakness, and irritability, lethargy, confusion, and muscle cramps. Clinical severity of hyponatremia depends on the absolute level of serum sodium concentration as well as the abruptness of onset [6].

CASE REPORT

62 years old female patient, pensioner, living with husband, two children; right-handed. The patient had never been a smoker, nor consumed alcohol. She started first time psychiatric outpatient treatment four years ago, because of development of depressive episode of moderate severity. It was preceded by the illness and death of her grandchildren. The patient was receiving TCA maprotiline 2x25 mg/day and bromazepam 2x3 mg/day with regular check-ups with a local psychiatrist in the Health center. Due to cardiologist-diagnosed hypertension and Type 2a dyslipidemia she used enalapril 2x10 mg/day (optionally, with an increase in blood pressure 2x20 mg/day), metoprolol 2x50 mg/day, nifedipine 5 mg/day, simvastatin 20 mg/day, as well as diclofenac (on demand, with the pain) and bromazepam 3 mg/day, on demand. She had no previous history of any endocrine diseases.

After a year of depression treatment with maprotiline and improving mood, there was a deterioration of general condition and appearance of confusion, unstable walking, cramps, along with an increase in blood pressure. At a local hospital was diagnosed hyponatremia (serum sodium concentration-112 mmol/L). Except elevated blood level of cholesterol, the other biochemical and hematological parameters as well as thyroid hormones were within normal ranges. Serum osmolarity was 244 mOsm/kg. Twenty-four hour urinary potassium was 75.3 mmol/L and 24h urinary sodium was 74.7 mmol/L. Computed tomography (CT) brain scan and radiological tests of other systems (X-ray of the heart and lungs and abdominal ultrasound) showed no pathological changes. Serum sodium level was normalized (137 mmol/L) by infusion of saline solution 0.9% and concentrated 10% saline solution and general condition of the patient improved. Except restriction of fluid intake, enalapril 2x10 mg/day, amlodipine 5 mg/day and hydrochlorothiazide 12.5 mg every 7 days were prescribed. After discharge from the Endocrinology Department, the patient con-
continued to take Maprotiline 2x25 mg/day and Bromazepam 3-6 mg/day, without consultation with her psychiatrist.

One year after the previous hospitalization, the patient was admitted to the Institute of Endocrinology of the tertiary level due to detailed re-examination, because of recurrent hyponatremia (117 mmol/l) which was corrected (144 mmol/l) with infusion therapy, conducted in Polyclinic of a local hospital. Blood level of glucose, thyroid-stimulating hormone (TSH), free thyroxine (fT4), luteinizing hormone (LH), estradiol, prolactin were in the normal ranges.

Low dose adrenocorticotrophic hormone (ACTH) test was normal, but the initial blood cortisol level was low as well as the base value of ACTH. Due to the low probability of hypocorticism, the Insulin Tolerance Test (ITT) [the gold standard for assessing the integrity of the hypothalamic-pituitary-adrenal (HPA) axis] was performed and its values were within normal limits (cortisol - 575.4 mmol/L, growth hormone - 6.7 mmol/L, and prolactin - 485.2 mmol/L). Serum osmolality was 296 mmol/L and urine osmolality was 215 mmol/L, during water restriction. Magnetic resonance imaging (MRI) of sellar region of pituitary gland showed no pathological changes.

Water test load (WTL) confirmed the Syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Imaging tests showed no pathological processes that could be the cause of SIADH, and a multi-slice computed tomography (MCTH) of lungs was performed, which showed no pathological changes. Bisoprolol 5mg/day for hypertension was prescribed along with restriction of fluid intake as well as dietary regimen. She also used bromazepam 3 mg/day and ginkgo biloba (prescribed from otologist for hearing disorder).

After discharge, the patient did not use antidepressants, was not heard from a psychiatrist and the mood was getting worse. She was shortly treated in Toxicology unit for taking bromazepam in excessive doses, “to treat insomnia”. The patient started outpatient’s psychiatric treatment at Psychiatric Department of tertiary level due to recurrent depressive episode of moderate severity, which was manifested by depressed mood, tearfulness, anxiety, lack of energy, occasional motor excitation, apathy, social restriction, and decrease in appetite, difficulty falling and staying asleep. The score of self-report The Beck Depression Inventory (BDI) [7] was 21.

The investigations that were conducted in the Institute for Endocrinology were excluded endocrine and other somatic causes of hyponatremia. Because her hyponatremia resolved after discontinuation of maprotiline therapy, maprotiline was thought to cause the patient’s SIADH in this case. We administered The Adverse Drug Reaction (ADR) Probability Scale [8]. This scale was developed in 1991. by Naranjo and others in order to standardize

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Do Not Know</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Are there previous conclusive reports on this reaction?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>+1</td>
</tr>
<tr>
<td>2. Did the adverse event appear after the suspected drug was administered?</td>
<td>+2</td>
<td>-1</td>
<td>0</td>
<td>+2</td>
</tr>
<tr>
<td>3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>+1</td>
</tr>
<tr>
<td>4. Did the adverse reaction reappear when the drug was readministered?</td>
<td>+2</td>
<td>-1</td>
<td>0</td>
<td>+2</td>
</tr>
<tr>
<td>5. Are there alternative causes (other than the drug) that could on their own have caused the reaction?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6. Did the reaction reappear when a placebo was given?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>+1</td>
</tr>
<tr>
<td>10. Was the adverse event confirmed by any objective evidence?</td>
<td>+1</td>
<td>0</td>
<td>0</td>
<td>+1</td>
</tr>
</tbody>
</table>

Total score = +8

Table 1. The Naranjo Adverse Drug Reaction (ADR) Probability Scale score
the assessment of causality for adverse drug reactions. The ADR Probability Scale consists of 10 questions that are answered as Yes, No, or “Do not know”. Total scores range from -4 to +13. The score of 9 or higher considered that the reaction is definite, probable if 5 to 8, possible if 1 to 4, and doubtful if 0 or less. According to the criteria of the Naranjo Adverse Drug Reaction Probability Scale, the likelihood of maprotiline use causing hyponatremia in this case was “probable” (total score=8) (Table1.).

The novel antidepressant mirtazapine (15 mg at bad time and after 7 days, 30 mg/day), with a dual mode of action (alpha 2 antagonist: enhances the release of norepinephrine and 5-HT1A–mediated serotonergic transmission) (noradrenaline and specific serotonergic antidepressants) (NaSSA) was implemented because of its low risk of hyponatremia. Before administration of mirtazapine, serum sodium level was 137 mmol/L. In addition to mirtazapine, the patient has used the first few months bromazepam. Based on self-reporting and family members reporting, the patients adhered to the prescribed pharmacological and non-pharmacological treatment.

After the administration of mirtazapine, in a patient there was a gradual reduction of depressive symptoms and the patient began to perform her daily activities. The BDI [7] score was 8. The patient is regularly controlled by the cardiologist, blood pressure is normalized (120/80 mmHg), and the current therapy is bisoprolol 2.5 mg/day, enalapril 10 mg/day (with an increase in blood pressure) and simvastatin 20 mg/day. Blood sodium levels were within normal limits over the past 18 months (the most recent value-141 mmol/l).

Given that weight gain is one of the most common side effects of mirtazapine, we have followed this parameter in particular. Body mass index (BMI) was 26.5 kg/m2 (body height=1.55 m, body weight=65 kg) before the initiation of mirtazapine treatment. Body weight of the patient wasn’t considerably changed during the mirtazapine treatment.

**DISCUSSION**

A case report of hyponatremia due to maprotiline treatment in patient with a diagnosis of depressive episode has clinical significance, because hyponatremia is a common and potentially dangerous side effect of the use of psychotropic drugs [2, 9, 10]. The findings of previous studies have shown that the highest incidence of this metabolic disorders is in the use of serotonergic ADs [11,12]. However, a case description of our patient draws attention to the possibility of development of hyponatremia associated with other classes of ADs that are considered not to have a high risk of this side effect.

As we showed in our patient’s report, hyponatremia may occur during the use of tricyclic antidepressant (TCA) maprotiline [which is sometimes classified as a tetracyclic antidepressant (TeTCA)] [13]. We conducted a detailed clinical, laboratory and other complementary tests [14,15], after which we excluded endocrine and other somatic diseases as possible causes of hyponatremia in our patients. AD maprotiline proved to be probable cause of this electrolyte imbalance. After discontinuation of the maprotiline therapy, the serum sodium levels were within normal ranges (131-137 mmol/L). According to the criteria of the Naranjo Adverse Drug Reaction Probability Scale, the likelihood of maprotiline use causing hyponatremia in this case was “probable” (score=8). This category includes that the reaction

a) followed a reasonable temporal sequence after a drug,

b) followed a recognized response to the suspected drug,

c) was confirmed by withdrawal but not by exposure to the drug, and

d) could not be reasonably explained by the known characteristics of the patient’s clinical state [8].

The association between the use of ADs and the changes of serum sodium concentration was first described precisely during the application of TCA - amitriptyline, 1974 [16]. And other research findings [17] suggested a considerable association between TCA and the occurrence of hyponatremia. The results of some recent studies [18] showed a lower incidence of hyponatremia in the application of TCAs (0.01% - 0.33%) in comparison with previous studies (16.7%) [19, 20], that can be explained by different methodological approaches (active monitoring, higher hyponatremia threshold).

The pathogenesis of hyponatremia in the use of TCAs is not clearly understood. The patient who was represented, diagnosed with the Syndrome of inappropriate antidiuretic hormone secretion (SIADH) [14,15], after en-
doctrine examination. This syndrome is usually considered as a cause of hyponatremia induced by ADs. Thus, Mannesse et al. [21] were observed in 50% of the sample recorded SIADH, and with 25% of “possible SIADH”. In patients with SIADH, more than half were “most likely” caused by the use of AD, in a third “possible”, while in one patient “suspected”.

Certain studies have shown that serotonergic mechanisms are involved in regulating the secretion of ADH [22,23], while other studies did not confirm it [24]. The animal studies have shown that both neurotransmitters, noradrenalin (NA) and serotonin (5-hydroxy tryptamine) (5-HT) may increase the secretion of ADH by stimulating alpha-adrenergic and serotonergic receptors [25]. Namely, in the study of Klein [26] has been shown that NA increases the excretion of sodium. It is known that both neurotransmitters, NA and 5-HT are involved in the control of secretion of arginine - vasopressin (AVP) [27]. Koelkebeck et al. [28] have pointed to the role of the NA in the development of hyponatremia in a case report of hyponatremia induced by reboxetine (noradrenergic reuptake inhibitor) (NRI). These findings may help in considering the mechanisms of hyponatremia with the administration of the drug, which is used by our patients, maprotiline, bearing in mind its pharmacological profile (enhances the NA level in the synaptic cleft, through the strong inhibition of its reuptake in the level of presynaptic neuron). Further research is necessary to elucidate the neurobiological mechanisms of occurrence of this undesired effect of AD therapy.

Hyponatremia in our patient was diagnosed after 12 months of the maprotiline treatment. According to several studies, TCA have attenuated risk profile for the development of hyponatremia in relation to other classes of ADs. So, later diagnosis of hyponatremia may be associated with a modest reduction in serum sodium level. Early symptoms of this disorder (fatigue, lethargy, weight loss) are nonspecific and can mimic the symptoms of psychiatric disorders. According to the literature, the time of occurrence of hyponatremia caused by the use of ADs varies greatly, and the results of the study has shown that this side effect of the drug may occur from one day to several months after starting therapy [29]. This information is important to bear in mind because of the necessity to increase awareness of physicians for this complication of AD therapy, and because of the possibility of its misdiagnosis. It is therefore recommended routine analyzed the serum sodium concentration in the first 2 weeks of therapy in patients with risk factors for development of this electrolytic disturbance as well as in those with lower serum sodium level at the beginning of the treatment. This is important, because the delayed recognition and treatment of hyponatremia can lead to irreversible neurological damage and death [30].

In our patient, there were several risk factors for the occurrence of this electrolyte disturbance: older age (60 yrs.), female sex and the use of concomitant antihypertensive therapy (ACE inhibitor enalapril) [4].

The results of numerous studies have shown that older patients (≥65 years) had more than six fold increased risk for hyponatremia than younger patients [2]. Bowman et al. [20] indicated that in approximately 25% of elderly patients on the treatment of ADs have occurred hyponatremia. According to Mannesse et al. [21], in the majority of patients older than 60 years, hyponatremia was caused by the use of TCAs (11.5%), followed by SSRIs (10.2%), venlafaxine (SNRIs) (8.6%) and mirtazapine (NaSSA) (5.6%). The reduction in renal blood flow, glomerular filtration rate and renal tubular damage concentration makes the elderly prone to the occurrence of hyponatremia. Aging also leads to changes in water balance due to changes in stimulating the release of vasopressin and changes in renal response to vasopressin [21]. These data are important because SSRIs are often used in the elderly because they have a more favorable adverse effects profile in relation to TCAs. However, there are studies which show that the occurrence of hyponatremia is not associated with age [21].

Another drug that the patient used to control hypertension, enalapril (in cotherapy with other antihypertensive agents), that, according to data from the literature, carries a risk for hyponatremia has continued to use even after maprotiline off, but there was no electrolyte imbalance. The results of Kirby et al. study [31] also showed that concomitant use of non-psychotropic drugs, such as ACE inhibitor in the treatment of arterial hypertension increases the risk of hyponatremia. Hypertension (and other somatic diseases, common in the elderly) [32] may impair the
severity of hyponatremia or mask its beginning [33].

Most studies show that women have greater risk for developing hyponatremia induced by AD therapy. Sex differences in occurrence of hyponatremia caused by AD were primarily associated with hormonal activity. Thus, estrogen (but not progesterone) stimulates the secretion of AVP [34], and women may have a higher sensitivity on ADH with an increase in the expression of vasopressin renal receptors [35]. However, there are studies, whose results have not shown the influence of sex on the incidence of hyponatremia with the use of AD therapy [2, 21].

To continue treatment with mirtazapine [36], we decided because of demonstrated lower incidence of hyponatremia during administration of this drug [24]. The research findings suggested that mirtazapine may be an alternative in the treatment of patients with increased risk of hyponatremia. Thus, the German multicenter drug surveillance program AMSP in psychiatric patients has not found a single case of the occurrence of hyponatremia induced by mirtazapine on a sample of 28172 patients [37]. The findings of retrospective study by Jung et al. [38] showed that none of the 76 patients on mirtazapine have developed hyponatremia compared to 8% of patients on SSRIs and 4% of patients on venlafaxine. During the implementation of mirtazapine, in our patient there was an improvement in mood and reduction of anxiety, irritability, and insomnia.

We continue to implement restrictions on fluid intake, dietary diet and regular check-ups with an endocrinologist and a cardiologist with regular monitoring of serum sodium, and other hematological and biochemical parameters.

CONCLUSION

Considering these facts, it can be concluded that in patients with different risk factors for developing hyponatremia, should determine serum sodium concentration, before and during the application of antidepressant therapy, because many patients may have undiscovered hyponatremia, which can be exacerbated by prescribing antidepressant.

In patients with the appearance of hyponatremia, it is necessary to carry out a detailed endocrine examination, in order to exclude other, somatic causes of this electrolyte disturbance. The restriction of fluid intake, along with discontinuation of antidepressant is the first strategies in the treatment. Better awareness and knowledge of risk factors associated with other classes of antidepressants for the development of hyponatremia can help clinicians in the choice of the drug, thus allowing safe treatment for patients at risk, particularly patients with a history of SIADH or those who are showing the first signs of hyponatremia during the current application of AD.

REFERENCES

11. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with...


23. Brownfield MS, Greathouse J, Lorenz SA, Armstrong J, Urban JH, Van de Kar LD. Neuropharmacological characterization of serotoninergic stimu-

Приказ случаја хипонатремије повезане са лечењем мапротилином

Жана Б. Стаковић1, Зорана З. Павловић1,3, Милица Ј. Јовићић1, Милош П. Žарковић2,3

1 Клиника за психијатрију, Клинички Центар Србије, Београд, Србија
2 Институт заендокринологију, дијабетес и болнести метаболизма, Клинички Центар Србије, Београд, Србија
3 Медички факултет, Универзитет у Београду, Београд, Србија

Кратак садржај

Увод: Мапротилин је трпички антидепресив (понекад класификован као тетрциклни антидепресив), који је претежно инхибитор поновног враћања норепинефрина/норадреналина, обично предписан за депресију.

Циљ: Приказати пацијенткину са депресивном епизодом и појавом хипонатремије током лечења мапротилином.

Приказ случаја: Код 62-годишња жена је диагностиковање депресивна епизода пре четири године. Она је лечена амбулантно мапротилином, 50 мг/дневно и бромазепамом 6 мг/дневно, код надлежног психијатра. Пацијенткина је такође користила еналаприл 2x10 мг/дневно, метопролол 2x50 мг/дневно, нифедипин 5 мг/дневно и симвастатин 20 мг/дневно за лечење хипертензије и дислипидемије. Након око 12 месеци употребе мапротилина, била је хоспитализована на Ендокринолошком одељењу локалне болнице због појаве конфузије, нестабилног хода, грчеља, као и појава крвног притиска. Тада је диагностиковања хипонатремија (ниво натријума у сеуму -112 ммоль/Л), коригована (137 ммоль/Л) употребом ренералне терапије. Пацијенткина је наставила да користи мапротилин без кonsултације са својим психијатром. Након годину дана, пацијенткина је (оново) хоспитализована на Ендокринолошком одељењу терцијарног нивоа ради деталног испитивања због рекурентне хипонатремије (117 ммоль/Л), кориговане (136 ммоль/Л) амбулантном пременом ренералне терапије у локалној болници. Применjen је тест оптерећења вodom и постављена дијагноза Sindroma neadekvatnог вре hипоталамус-хипофиза-надбубрег. Антидепресив миртазапин (15 мг/дневно) је уведен због поновне појаве депресије. Током тремтmana митразапином је опсевировано постепено смањење депресивних симптома. Антихипертензивна терапија, ограњење унosa течности и дигететски ређим се и далje примењују. Концентрације натријума у сеуму су биле у нормалним границима протеклих 18 месеци.

Закључак: Ниво натријума у сеуму треба мерити пре и током терапије било којом класом антидепресива, способно код оних пацијенаца са појаваним ризиком од појаве хипонатремије.

Кључне рећи: антидепресиви, нејелени ефекти, хипонатрамија, мапротилин, митразапин

Received: April 6, 2015
Accepted: May 15, 2015